The German Federal Joint Committee (G-BA) plans to decide on reimbursement of breast cancer biomarker tests in Q4.
With a University of Missouri partnership, Roche is testing the combination of data from disparate sources and furthering the integration of several recent acquisitions.
The company outlined its plans to launch a kidney transplant rejection test that is based on cell-free DNA in 2019 and described its progress in breast cancer research.
Proceeds will be used to support studies for regulatory submissions to the FDA for the company's metastatic breast cancer test, among other things.
A new company will be established to develop a service platform using blockchain technology for medical services and personalized health management.
The Belgian cancer center plans to evaluate Natera's ctDNA assay for evaluating response and detecting minimal residual disease in breast cancer patients.
The study solidified how doctors should interpret and act upon an intermediate result from the breast cancer risk test in how to treat early-stage patients.
The company is now commencing a trial of the test platform in 250 patients to generate more data while it considers how to best commercialize it.
In a new analysis of the trial, researchers concluded that women over the age of 50 with recurrence scores below 25 appear to see no added benefit from adjuvant chemo.
Under the deal, Singapore-based Angsana Molecular & Diagnostics Laboratory will offer the two tests in markets including Singapore.